Ketamine Hydrochloride

$4 million upfront with up to approximately $7.7 million of potential additional gross proceeds upon the exercise in full of warrants in cash SARASOTA, FLA., July 10, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a diversified developmental-stage biopharmaceutical company with a therapeutic focus on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases, today announced that it has entered into definitive agreements for the issuance and sale of 619,965 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-3 warrants to purchase up to an aggregate of 619,965 shares of common stock and short-term Series A-4 warrants to purchase up to an aggregate of 619,965 shares of common stock, at a purchase price of $6.452 per share (or pre-funded warrant in lieu thereof) and associated warrants in a private placement priced at-the-market under Nasdaq rules. The warrants will have an exercise price of $6.21 per share and will be exercisable immediately upon issuance. The Series A-3 warrants will expire five years after the effective date of the Resale Registration Statement (as defined below) and the short-term Series A-4 warrants will expire eighteen months after the effective date of the Resale Registration Statement. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The aggregate gross proceeds to the Company from the offering are expected to be approximately $4 million, before deducting placement agent fees and other offering expenses payable by the Company. The potential additional gross proceeds to the Company from the warrants, if fully exercised on a cash basis, will be approximately $7.7 million. No assurance can be given that any of the warrants will be exercised, or that the Company will receive cash proceeds from the exercise of the warrants. The offering is expected to close on or about July 10, 2026, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes. The securities described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”) and Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants sold in the offering, have not been registered under the Act or applicable state securities laws. Accordingly, such securities may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. Pursuant to a registration rights agreement, the Company has agreed to or more registration statements with the SEC covering the resale of the unregistered securities to be issued in the offering (the “Resale Registration Statement”). This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. About Silo Pharma, Inc. Silo Pharma is a diversified developmental-stage biopharmaceutical company with a therapeutic focus on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for post-traumatic stress disorder (PTSD), SP-26 for fibromyalgia and chronic pain, and a preclinical asset targeting Alzheimer’s disease. Silo’s research is conducted in collaboration with leading universities and laboratories. silopharma.com Forward Looking Statements This news release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including statements about the completion of the offering, the satisfaction of customary closing conditions related to the offering, the intended use of proceeds from the offering, the potential exercise of the warrants prior to their expiration and potential proceeds therefrom, changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law. Contact (800) 705-0120 investors@silopharma.com

Rx Bandz ...has demonstrated a strong ability to execute on complex government-funded programs, and we are pleased to continue supporting their progress as they advance toward FDA submission.”” — James Parker, Co-Founder, Leonid Capital Partners DENVILLE, MA, UNITED STATES, July 9, 2026 / EINPresswire.com / -- Rx Bandz , a medical device platform company (“Rx Bandz” or the “Company”), with over a dozen US military R&D contracts to develop next-generation drug delivery technologies, today announced that it has closed an advance with Leonid Capital Partners . Financial terms of the transaction were not disclosed. This third tranche financing builds on Leonid’s initial 2024 credit facility, providing non-dilutive capital to support the manufacturing of Rx Bandz’s proprietary MiniJect ® auto-injector platform for submission to the FDA. Rx Bandz expects to submit to the FDA in late 2026. The submission represents a significant regulatory milestone for the MiniJect platform and will support future partnerships with pharmaceutical companies seeking advanced injectable drug delivery solutions. Since its founding, Rx Bandz has been awarded over $30 million in U.S. military R&D contracts to develop innovative drug delivery technologies designed to improve medical readiness and patient care in demanding environments. Rx Bandz’s ketamine and hydromorphone auto-injector programs have advanced to Phase III SBIR contracts with the U.S. Air Force’s 711th Human Performance Wing Advanced Development, demonstrating the Company’s ability to transition military R&D programs into sustained federal production. “We are honored by Leonid’s continued confidence in our team and our mission to address critical military healthcare needs through innovative drug delivery technology,” said Jessica Walsh , Founder and Chief Executive Officer of Rx Bandz. “MiniJect was designed to provide military personnel, first responders, and patients with a smaller, more rugged, and easier-to-use auto-injector capable of delivering life-saving medications from the home to the battlefield.” James Parker, Co-Founder of Leonid Capital Partners, said, “Rx Bandz is developing technology that has the potential to improve medical readiness for our warfighters. Their team has demonstrated a strong ability to execute on complex government-funded programs, and we are pleased to continue supporting their progress as they advance toward FDA submission.” The Company plans to use the proceeds of Leonid Capital Partners advance to continue developing therapeutics focused on battlefield pain management. These formulations for MiniJect also have “dual use” commercial applications to serve the non-military patient and emergency markets, including postpartum hemorrhage, antibiotic treatment, and major depressive disorder. MiniJect’s proprietary platform delivers everything from small molecules to biologics and other highly viscous therapeutics, enabling broad pharmaceutical applications across military and civilian markets. The Company is currently engaged in licensing discussions with multiple pharmaceutical companies. “We appreciate Leonid’s continued support as we execute our development roadmap and prepare for FDA submission,” said Harsha Murthy, Chief Strategy Officer and a member of the Rx Bandz Board of Directors. “Completion of our Device Master File and submission to the FDA will position MiniJect as an attractive platform for pharmaceutical partners seeking innovative delivery solutions for military, civilian, and emergency medicine applications.” Murthy noted that because MiniJect is a combination product platform, development efforts are currently focused on manufacturing validation, reliability testing, and human factors studies required to support FDA submission. “This advance extends our operational runway through FDA submission while preserving the option of our current $8 million Series A round. Financing against our government contract portfolio is a capital efficient way to convert program execution into working capital, and Leonid has been a thoughtful partner across each stage of the facility,” said Christopher Taylor, Chief Financial Officer of Rx Bandz. Leonid Capital Partners is a leading provider of venture debt financing for companies developing technologies that support national security and other strategic government priorities. By accepting government contracts as collateral, Leonid provides non-dilutive growth capital tailored to scientists, engineers, and technology innovators performing under a broad range of U.S. government contract vehicles that accelerate research, product development, and mission-critical technologies. About Rx Bandz Rx Bandz is a privately held, multi-asset medical device company developing a platform of patient-centric auto-injectors and proprietary drug formulations. From its laboratory in Denville, New Jersey, the company is advancing a new generation of compact, portable auto-injectors designed to improve the delivery of injectable medications for military personnel, emergency medical services (EMS), and patients in home-care settings. Its lead platform, MiniJect, is being developed to deliver critical emergency medications, including epinephrine for anaphylaxis, ketamine and hydromorphone for pain management, with rapid deployment, intuitive operation, and enhanced portability. The platform is designed to expand access to life-saving therapies, such as tranexamic acid for hemorrhages and antibiotics, across prehospital, battlefield, and home environments. Beyond MiniJect, Rx Bandz is developing a versatile family of auto-injectors capable of delivering less than 1 mL to 5 mL injectable therapies across a broad range of medication viscosities. By integrating innovative device engineering with proprietary drug formulations, the company aims to make injectable treatments simpler, more reliable, and accessible by anyone, anywhere, anytime. Learn more at www.rxbandz.com About Leonid Capital Partners Leonid Capital Partners invests capital into critical national security initiatives. The firm leverages its deep government and technical expertise to provide its portfolio companies with the flexible resources they need to grow their business. Learn more at leonidfinance.io Nothing herein shall be construed as, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy or hold, an interest in any security or investment Myrna Walsh Rx Bandz Myrna@Rxbandz.com Visit us on social media: YouTube Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.